FDA-cleared profile

qXR-LN

Qure.ai Technologies · X-ray/Radiography · FDA-cleared (510(k))

Authorized purpose: Second-reader CADe to identify and mark suspected pulmonary nodules 6-30 mm in the incidental adult population

Clinical role
Second-reader CADe detection and localization, operating as an adjunct to physician review rather than standalone clinical decision-making
Images and patients
X-ray/Radiography · Chest/lung, focused on suspected pulmonary nodules
Key limitation
Keep in mind: Incidental adult population and frontal AP/PA digital chest radiographs only; target range 6-30 mm; adjunctive second-reader information, not standalone clinical decision-making and not a substitute for the original radiograph

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Second-reader CADe to identify and mark suspected pulmonary nodules 6-30 mm in the incidental adult population
  • Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Chest/lung, focused on suspected pulmonary nodules Input: DICOM frontal AP or PA digital chest radiographs of adults; effective target nodule size 6-30 mm
  • Who uses it?Intended users: Radiologists, emergency-room physicians, or pulmonologists who regularly review chest X-rays
  • What does the software produce?Output: DICOM output with ROI markings on a duplicated input image showing the presence and location of suspected pulmonary nodules; output is for adjunctive review and does not rule out the target condition
  • What is its most important limitation?Key limitation: Incidental adult population and frontal AP/PA digital chest radiographs only; target range 6-30 mm; adjunctive second-reader information, not standalone clinical decision-making and not a substitute for the original radiograph

Clinical takeaway. Clinical role: Second-reader CADe to identify and mark suspected pulmonary nodules 6-30 mm in the incidental adult population

Evidence takeaway. Evidence from the reviewed source record: Standalone study covered 8 states and 40 US sites, with ground truth from five ABR-certified readers using chest radiographs plus CT and reports. qXR-LN nodule-level sensitivity was 84.1% (reported CI 77.97%-97.24%) and FPPI 0.18 (0.14-0.22). Scan-level AUC was 94.51 (92.64-96.66), sensitivity 93.83 (88.94-97.00), and specificity 81.09 (76.30-85.00). In the MRMC second-read study, AFROC was 0.8095 aided versus 0.7333 unaided, delta 0.07621, p<1e-5; nodule-level sensitivity improvement was 11.96 percentage points

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Second-reader CADe to identify and mark suspected pulmonary nodules 6-30 mm in the incidental adult population
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Second-reader CADe detection and localization, operating as an adjunct to physician review rather than standalone clinical decision-making
  • Exact FDA submission
  • Checked 2026-09-08
Required input
DICOM frontal AP or PA digital chest radiographs of adults; effective target nodule size 6-30 mm
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
DICOM output with ROI markings on a duplicated input image showing the presence and location of suspected pulmonary nodules; output is for adjunctive review and does not rule out the target condition
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Incidental adult chest-radiograph review in routine clinical workflow; the packet does not restrict the product to a named institutional setting
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Radiologists, emergency-room physicians, or pulmonologists who regularly review chest X-rays
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Incidental adult population and frontal AP/PA digital chest radiographs only; target range 6-30 mm; adjunctive second-reader information, not standalone clinical decision-making and not a substitute for the original radiograph
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
Standalone study covered 8 states and 40 US sites, with ground truth from five ABR-certified readers using chest radiographs plus CT and reports. qXR-LN nodule-level sensitivity was 84.1% (reported CI 77.97%-97.24%) and FPPI 0.18 (0.14-0.22). Scan-level AUC was 94.51 (92.64-96.66), sensitivity 93.83 (88.94-97.00), and specificity 81.09 (76.30-85.00). In the MRMC second-read study, AFROC was 0.8095 aided versus 0.7333 unaided, delta 0.07621, p<1e-5; nodule-level sensitivity improvement was 11.96 percentage points
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Standalone study covered 8 states and 40 US sites, with ground truth from five ABR-certified readers using chest radiographs plus CT and reports. qXR-LN nodule-level sensitivity was 84.1% (reported CI 77.97%-97.24%) and FPPI 0.18 (0.14-0.22). Scan-level AUC was 94.51 (92.64-96.66), sensitivity 93.83 (88.94-97.00), and specificity 81.09 (76.30-85.00). In the MRMC second-read study, AFROC was 0.8095 aided versus 0.7333 unaided, delta 0.07621, p<1e-5; nodule-level sensitivity improvement was 11.96 percentage points
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
93.83% (95% CI: 88.94%, 97%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
81.09% (95% CI: 76.30%, 85%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

qXR-LN regulatory performance study summary

  • DesignStand-alone performance and reader study (ACR AI Central category)
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K231805
  • Sites40
  • IndependenceIndependence not established

K231805

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K231805. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM frontal AP or PA digital chest radiographs of adults; effective target nodule size 6-30 mm

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K231805: qXR-LN

  2. Routing

    Source context, not route validation: Images are sent through a PACS or other radiological image-storage system, and the device is intended for use with any DICOM viewer or PACS; exact local interface/version compatibility is not established

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K231805: qXR-LN

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 ·

  4. Returned objects

    Source context, not route validation: DICOM output with ROI markings on a duplicated input image showing the presence and location of suspected pulmonary nodules; output is for adjunctive review and does not rule out the target condition

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K231805: qXR-LN

  5. Viewer/worklist/report

    Unresolved route: DICOM output with ROI markings on a duplicated input image showing the presence and location of suspected pulmonary nodules; output is for adjunctive review and does not rule out the target condition

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K231805: qXR-LN

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Images are sent through a PACS or other radiological image-storage system, and the device is intended for use with any DICOM viewer or PACS; exact local interface/version compatibility is not established
  • Exact FDA submission
  • Checked 2026-09-08
Security
Qure.ai's documentation FAQ says data is sent over HTTPS (TLS 1.2 or higher), stored encrypted at rest with AES-256-GCM, backed up with restore tests twice a year, and that Qure maintains an ISO 27001 certification with periodic surveillance audits. It also says hospitals anonymize PHI before sending data. The certificate itself was not read and no date or scope is given.
  • Vendor-wide
  • Checked 2026-10-25

Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.

Monitoring
Qure.ai's vulnerability disclosure programme states that it covers all Qure.ai commercial products, including cloud-hosted products and Qure.ai-operated infrastructure, and commits to handling every report promptly and transparently with an acknowledgement and tracking reference within 2 business days.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. The page names Qure.ai generally and does not scope these commitments to any specific product release; exact-release scope is not established. The programme is an intake and response-handling commitment; it makes no uptime, drift or continuous-monitoring claims.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for qXR-LN; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K231805
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Chest/lung, focused on suspected pulmonary nodules
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-12-22
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
10Source classes checked
0Screened PubMed leads
2Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 0 PubMed and 2 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 0 PubMed and 2 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K231805 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission

    The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

9 sources - 3 history items

Source ledger

  1. FDA K231805: qXR-LN

    U.S. Food and Drug Administration - Published 2023-12-22 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. qXR-LN model card (K231805)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K231805

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  8. Qure.ai Documentation: Security and Privacy FAQ

    Qure.Ai Technologies - Accessed 2026-10-25

    Scope: security

  9. Qure.ai Vulnerability Disclosure Programme

    Qure.ai - Accessed 2026-10-27

    Scope: security, monitoring

Research history

  1. K231805 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K223133

VisiRad XR

Imidex Inc.

Authorized purpose: VisiRad XR is a computer-aided detection device that identifies and marks regions of interest suspicious for lung nodules and masses measuring 6-60 mm on chest radiographs in patients older than 21 years in outpatient or emergency-department settings.

Modality
X-ray/Radiography
Anatomy
Adult chest and pulmonary nodules or masses 6-60 mm
Decision
2023-08-03
FDA-approved P000041

RAPIDSCREEN RS-2000

RIVERAIN MEDICAL GROUP

Authorized purpose: RAPIDSCREEN RS-2000 is a PMA-authorized computer-aided detection device that identifies and marks regions of interest on digitized frontal chest radiographs associated with solitary pulmonary nodules 9-30 mm, as an aid after the physician's initial interpretation.

Modality
X-ray/Radiography
Anatomy
Adult chest; solitary pulmonary nodules 9-30 mm
Decision
2001-07-12
FDA-cleared K252953

Velmeni for Dentists (V4D) Endo-Perio

Velmeni, Inc.

Authorized purpose: Concurrent-read CADe to assist dentists in detecting specified tooth and jaw anatomy, bone-level landmarks, and root-canal-treated teeth in digital radiographs of permanent teeth in patients 15 years or older.

Modality
X-ray/Radiography
Anatomy
Permanent teeth and jaw/maxillofacial anatomy, including enamel, dentine, pulp, root, mental foramen, inferior alveolar canal, maxillary sinus, cementoenamel junction, crestal bone, and root-canal-treated teeth
Decision
2026-05-11
FDA-cleared K253502

Critical Care Suite with Enteric Tube Positioning AI Algorithm

Ge Medical Systems, LLC

Authorized purpose: Analyze frontal chest and abdominal X-ray images to detect and localize a nasally or orally inserted enteric tube, its tip and side port if present, and the diaphragm and airways for radiologist review.

Modality
X-ray/Radiography
Anatomy
Chest/lung and abdomen/stomach; enteric tube, tube tip and side port, diaphragm, and airways including carina and left/right bronchi
Decision
2026-04-14

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history